Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jokubaitis Vilija G, Alroughani Raed, Altintas Ayse, Eichau Sara, Hughes Stella, Willekens Barbara, Horakova Dana, Havrdova Eva Kubala, Ozakbas Serkan, Boz Cavit, Habek Mario, Kalincik Tomas, Roos Izanne, Etemadifar Masoud, Peterka Marek, Lechner-Scott Jeannette, Meca-Lallana Jose E, Rous Zuzana, Houskova Jana, Prat Alexandre, Girard Marc, Ampapa Radek, Buzzard Katherine, Skibina Olga, John Nevin A, Kermode Allan G, Fabis-Pedrini Marzena J, Foschi Matteo, Surcinelli Andrea, Blanco Yolanda, Baghbanian Seyed Mohammad, Gerlach Oliver, Macdonell Richard, Pavelek Zbysek, Stourac Pavel, McCombe Pamela, Laureys Guy, Butzkueven Helmut, van der Walt Anneke, Gray Orla, MSBase Study Investigators
Аннотация
OBJECTIVE: To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women's Health Registry.
METHODS: We report summary statistics for data collected between May 2020 and August 2024.
RESULTS: A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen.
CONCLUSION: This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally.